Hamlet Pharma & SelectImmune Pharma invites to a digital investor meeting on April 3rd and April 4th at 12.00 CET
Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections, an additional pharmaceutical project with patent rights for the treatment of tuberculosis is acquired. Read the full press release on the websites for Hamlet Pharma and SelectImmune.
Hamlet Pharma & SelectImmune are inviting you to a digital investors’ meeting via Zoom, on Monday and Tuesday, April 3rd and April 4th of at 12.00 CET, for dialogue about the merger. We welcome existing owners, other investors and interested parties to join. The meeting participants will be informed of the company developments and will be invited to ask questions. These may be asked online during the meeting or be sent via e-mail to the addresses listed below. The meeting will be held in Swedish with presentation slides in English. Please use these links to participate:
Monday 3rd of April at 12 CET:
https://us06web.zoom.us/j/86082931807?pwd=ekViYnFHTTUxYTRIZHQ2RVd5NEVYdz09
Tuesday 4th of April at 12 CET:
https://us06web.zoom.us/j/89697967748?pwd=NStwRUxGZ3hmdGE4elJsbXRkbmE3Zz09
For more information, contact
Catharina Svanborg
Phone +46-709-426549
Jan Zetterberg
Phone: +46-705-544300
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.
